A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib - Study Drug AMN107

  • Markowitz, Avi (PI)

    Project: Research project

    Project Details

    StatusActive
    Effective start/end date6/1/13 → 1/30/25

    Funding

    • Novartis Pharmaceuticals Corporation: $30,429.00